Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anemia Prevention
Study results from Emory University, Department of Medicine provide new insights into anemia prevention
July 10th, 2007
Researchers detail in "Effect of anemia on hemorrhagic complications and mortality following percutaneous coronary intervention," new data in anemia. "The relation across anemia, hemorrhagic complications, and mortality associated with percutaneous coronary intervention (PCI) is unclear. We reviewed the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 Trial, which compared bivalirudin plus provisional glycoprotein IIb/IIIa blockade with heparin plus planned glycoprotein IIb/IIIa blockade in patients undergoing urgent or elective PCI," scientists in the United States report. "Of the 6,010 patients randomized in REPLACE-2, 1,371 (23%)...
Source: Drug Law Weekly (2007-07-10)
|
